The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Open accessAbstract
Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Peptide ReACp53 was described to prevent the amyloid-like aggregation of proteins with point mutations in p53-R248Q or p53-R175H.”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of ovarian cancer xenografts with ReACp53 resulted in decreased cell proliferation and tumor reduction [134].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janzen, D. M., Tiourin, E., Salehi, J. A., Paik, D. Y., Lu, J. N., Pellegrini, M. A., & Memarzadeh, S. (2015) · Nature Communications · doi:10.1038/ncomms8956 · Cited by 69
Self-citationRetractedSiegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Atomic structures of amyloid cross-β spines reveal varied steric zippers
Sawaya, M. R., Sambashivan, S., Nelson, R. A., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J. W., McFarlane, H. T., et al. (2007) · Nature · doi:10.1038/nature05695 · Cited by 2,279
Self-citationThe first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Flagged first, then by citations
1 of the 61 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 343
Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer
Guo, T., Dong, X., Xie, S., Zhang, L., Zeng, P., & Zhang, L. (2021) · Cancer Management and Research · doi:10.2147/cmar.s292992 · Cited by 59
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 58
Pharmacological activation of wild-type p53 in the therapy of leukemia
Kojima, K., Ishizawa, J., & Andreeff, M. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.014 · Cited by 53
TP53 mutations in head and neck cancer
Nathan, C. O., Khandelwal, A. R., Wolf, G. T., Rodrigo, J. P., Mäkitie, A. A., Saba, N. F., Forastiere, A. A., Bradford, C. R., & Ferlito, A. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23385 · Cited by 55
Thermodynamic and Evolutionary Coupling between the Native and Amyloid State of Globular Proteins
Langenberg, T., Gallardo, R. U., van der Kant, R., Louros, N. N., Michiels, E., Duran‐Romaña, R., Houben, B., Cassio, R. F., Wilkinson, H. R., Garcia, T., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.076 · Cited by 51
Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
Jin, M., Xia, B.-R., Xu, Y., & Jin, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00598 · Cited by 50
Zhang, B., Shi, X., Xu, G., Kang, W., Zhang, W., Zhang, S., Cao, Y. Q., Qian, L., Zhan, P., Yan, H., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13063 · Cited by 50
Pedrote, M. M., de Oliveira, G. A. P., Felix, A. L., Mota, M. F., Marques, M. A., Soares, I. N., Iqbal, A., Norberto, D. R., Gomes, A. M. O., Gratton, E., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003285 · Cited by 51
Emerging Implications of Phase Separation in Cancer
Ren, J., Zhang, Z., Zong, Z., Zhang, L., & Zhou, F. (2022) · Advanced Science · doi:10.1002/advs.202202855 · Cited by 48
Lebedev, I., Nemajerová, A., Foda, Z. H., Kornaj, M., Tong, M., Moll, U. M., & Seeliger, M. A. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.001 · Cited by 48
Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations
Jarosz, D. F., & Khurana, V. (2017) · Cell · doi:10.1016/j.cell.2017.10.047 · Cited by 46
p53 and Zinc: A Malleable Relationship
Ha, J., Prela, O., Carpizo, D. R., & Loh, S. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.895887 · Cited by 48
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 47
Function and Regulation of Phase-Separated Biological Condensates
Li, X., Chavali, P. L., Pancsa, R., Chavali, S., & Babu, M. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01228 · Cited by 45
Research Progress Evaluating the Function and Mechanism of Anti-Tumor Peptides
Pan, X., Xu, J., & Jia, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s232708 · Cited by 46
Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities
Kumari, S., Sharma, V., Tiwari, R., Maurya, J. P., Subudhi, B. B., & Senapati, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174807 · Cited by 47
Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
Zhang, Y., Xu, L., Chang, Y., Li, Y., Butler, W., Jin, E., Wang, A., Tao, Y., Chen, X., Liang, C. Y., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0172-z · Cited by 44
Scuto, M. C., Salinaro, A. T., Caligiuri, I., Ontario, M. L., Greco, V., Sciuto, N., Crea, R., Calabrese, E. J., Rizzolio, F., Canzonieri, V., et al. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111551 · Cited by 43
A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils
Saelices, L., Nguyen, B. A., Chung, K., Wang, Y., Ortega, A., Lee, J. H., Coelho, T., Bijzet, J., Benson, M. D., & Eisenberg, D. S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005257 · Cited by 43
Self-citationLei, J., Qi, R., Tang, Y., Wang, W., Wei, G., Nussinov, R., & Ma, B. (2018) · The FASEB Journal · doi:10.1096/fj.201801973r · Cited by 45
Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma
Lin, Y., Liao, K., Miao, Y., Qian, Z., Fang, Z., Yang, X., Nie, Q., Jiang, G., Liu, J., Yu, Y., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz155 · Cited by 42
p53 amyloid aggregation in cancer: function, mechanism, and therapy
Li, J., Guo, M., Chen, L., Chen, Z., Fu, Y., & Chen, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00317-7 · Cited by 41
Haque, E., Kamil, M., Hasan, A., Irfan, S., Sheikh, S., Khatoon, A., Nazir, A., & Mir, S. S. (2019) · Glycobiology · doi:10.1093/glycob/cwz073 · Cited by 42
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 38
Haque, E., Kamil, M., Irfan, S., Sheikh, S., Hasan, A., Nazir, A., & Mir, S. S. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.014 · Cited by 39
Boeynaems, S., Tompa, P., & Bosch, L. V. D. (2018) · Cell Division · doi:10.1186/s13008-018-0034-4 · Cited by 39
Fan, Y., Yue, J., Xiao, M., Han‐Zhang, H., Wang, Y. V., Ma, C., Deng, Z., Li, Y., Yu, Y., Wang, X., et al. (2017) · eLife · doi:10.7554/elife.26129 · Cited by 42
Bifunctional ligand design for modulating mutant p53 aggregation in cancer
Miller, J. J., Blanchet, A., Orvain, C., Nouchikian, L., Reviriot, Y., Clarke, R. M., Martelino, D., Wilson, D. J., Gaiddon, C., & Storr, T. (2019) · Chemical Science · doi:10.1039/c9sc04151f · Cited by 40
Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?
Lim, D. V., Woo, W. H., Lim, J. X., Loh, X. Y., Soh, H. T., Lim, S. Y. A., Lee, Z. Y., Yow, H.-Y., Hamzah, S. B., Sellappans, R., et al. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230914090621 · Cited by 36
Tao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 35
Matthes, D., Gapsys, V., Brennecke, J. T., & de Groot, B. L. (2016) · Scientific Reports · doi:10.1038/srep33156 · Cited by 34
A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity
Liang, L., Wang, H., Shi, H., Li, Z., Yao, H., Bu, Z., Song, N., Li, C., Xiang, D., Zhang, Y., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.03.010 · Cited by 34
Inhibition of p53 protein aggregation as a cancer treatment strategy
Kwan, K., Castro-Sandoval, O., Gaiddon, C., & Storr, T. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102230 · Cited by 35
New Insights into the Roles of p53 in Central Nervous System Diseases
Li, H., Zhang, Z., Li, H., Pan, X., & Wang, Y. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad030 · Cited by 37
Targeting mutant p53 stabilization for cancer therapy
Wang, J., Liu, W., Zhang, L., & Zhang, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1215995 · Cited by 39
Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
Babamohamadi, M., Babaei, E., Salih, B. A., Babamohammadi, M., Azeez, H. J., & Othman, G. Q. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903075 · Cited by 39
Arsic, N., Slatter, T. L., Gadéa, G., Villain, É., Fournet, A., Kazantseva, M., Allemand, F., Sibille, N., Sevéno, M., de Rossi, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25550-2 · Cited by 33
BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate
Huang, X., Shi, D., Zou, X., Wu, X., Huang, S., Kong, L., Yang, M., Xiao, Y., Chen, B., Chen, X., et al. (2022) · Theranostics · doi:10.7150/thno.78492 · Cited by 33
Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2023) · Cancers · doi:10.3390/cancers15020448 · Cited by 38
Zhang, Y., Hu, Y., Wang, J.-L., Yao, H., Wang, H., Liang, L., Li, C., Shi, H., Chen, Y., Fang, J.-Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.152 · Cited by 32
Park, S.-K., Park, S., Pentek, C., & Liebman, S. W. (2020) · iScience · doi:10.1016/j.isci.2020.102000 · Cited by 35
Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
Saleh, A., & Perets, R. (2021) · Cancers · doi:10.3390/cancers13143465 · Cited by 33
Matis, I., Delivoria, D. C., Mavroidi, B., Papaevgeniou, N., Panoutsou, S., Bellou, S., Papavasileiou, K. D., Linardaki, Z. I., Stavropoulou, A. V., Vekrellis, K., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0144-3 · Cited by 32
Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties
Garg, A., Hazra, J. P., Sannigrahi, M. K., Rakshit, S., & Sinha, S. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.12.015 · Cited by 31
Fan, S., Wang, Y., Zhang, Z., Lu, J. L., Wu, Z., Shan, Q., Sun, C., Wu, D., Li, M., Sheng, N., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26797 · Cited by 31
Self-citationRecent advances in genitourinary tumors: A review focused on biology and systemic treatment
del Alba, A. G., Arranz, J. Á., Puente, J., Méndez-Vidal, M. J., Gallardo, E., Grande, E., Pérez‐Valderrama, B., González‐Billalabeitia, E., Lázaro-Quintela, M., Pinto, Á., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.010 · Cited by 30
Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53
Loh, S. N. (2020) · Biomolecules · doi:10.3390/biom10020303 · Cited by 30
p53 and its mutants on the slippery road from stemness to carcinogenesis
Molchadsky, A., & Rotter, V. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw092 · Cited by 30
HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53‐dependent mitochondrial apoptosis
Castelli, M., Piobbico, D., Chiacchiaretta, M., Brunacci, C., Pieroni, S., Bartoli, D., Gargaro, M., Fallarino, F., Puccetti, P., Soddu, S., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948073 · Cited by 29
Palmitoylation of gasdermin D directs its membrane translocation and pore formation in pyroptosisPreprint
Balasubramanian, A., Ghimire, L., Hsu, A. Y.-H., Kambara, H., Liu, X., Hasegawa, T., Xu, R., Tahir, M., Yu, H., Lieberman, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.21.529402 · Cited by 30
Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
Iwahashi, N., Ikezaki, M., Komohara, Y., Fujiwara, Y., Noguchi, T., Nishioka, K., Sakai, K., Nishio, K., Ueda, M., Ihara, Y., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac128 · Cited by 29
Interplay between posttranslational modifications and liquid‒liquid phase separation in tumors
Yan, X., Zhang, M., & Wang, D. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216614 · Cited by 27
Physiology and pharmacological targeting of phase separation
Wang, F., & Zhang, Y. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00993-z · Cited by 29
Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets
Petronilho, E. C., de Andrade, G. C., de Sousa, G. D. S., de Almeida, F. P., Mota, M. F., Gomes, A. V. D. S., Pinheiro, C. H. S., da Silva, M. C., Arruda, H. R. S., Marques, M. A., et al. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01289-x · Cited by 29
Current insights into the regulation of programmed cell death by TP53 mutation in cancer
Su, Y., Sai, Y., Zhou, L., Liu, Z., Du, P., Wu, J., & Zhang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023427 · Cited by 29
The Development of p53-Targeted Therapies for Human Cancers
Lu, Y., Wu, M. Y., Xu, Y., & Yu, L. (2023) · Cancers · doi:10.3390/cancers15143560 · Cited by 30
Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro
Chen, Z., Chen, J., Keshamouni, V. G., & Kanapathipillai, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.111 · Cited by 28
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 30
Salvation of the fallen angel: Reactivating mutant p53
Yang, L., Wang, Z., Chen, Y., Petersen, R. B., Zheng, L., & Huang, K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14572 · Cited by 27
Direct evidence of cellular transformation by prion-like p53 amyloid infection
Navalkar, A., Pandey, S., Singh, N., Patel, K., Datta, D., Mohanty, B. S., Jadhav, S. H., Chaudhari, P. R., & Maji, S. K. (2021) · Journal of Cell Science · doi:10.1242/jcs.258316 · Cited by 27
Chemo-Preventive Action of Resveratrol: Suppression of p53—A Molecular Targeting Approach
Akter, R., Rahman, M. H., Kaushik, D. K., Mittal, V., Uivaroșan, D., Nechifor, A. C., Behl, T., Karthika, C., Stoicescu, M., Munteanu, M. A., et al. (2021) · Molecules · doi:10.3390/molecules26175325 · Cited by 28
Nucleic acid actions on abnormal protein aggregation, phase transitions and phase separation
Silva, J. L., Vieira, T. C. R. G., Cordeiro, Y., & de Oliveira, G. A. P. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102346 · Cited by 27
Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant
Lei, J., Qi, R., Wei, G., Nussinov, R., & Ma, B. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06538k · Cited by 27
Insights into amyloid-like aggregation of H2 region of the C-terminal domain of nucleophosmin
Russo, A., Diaferia, C., Manna, S. L., Giannini, C., Sibillano, T., Accardo, A., Morelli, G., Novellino, E., & Marasco, D. (2016) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2016.11.006 · Cited by 28
Phase separation-mediated biomolecular condensates and their relationship to tumor
Wang, X., Liu, J., Mao, C., & Mao, Y. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01518-9 · Cited by 25
GOF Mutant p53 in Cancers: A Therapeutic Challenge
Dolma, L., & Muller, P. A. J. (2022) · Cancers · doi:10.3390/cancers14205091 · Cited by 29
Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates
Maritschnegg, E., Heinzl, N., Wilson, S., Deycmar, S., Niebuhr, M., Klameth, L., Holzer, B., Kozieł, K., Concin, N., & Zeillinger, R. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02373 · Cited by 24
Pharmacological targeting of mutant p53
Kogan, S., & Carpizo, D. R. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.11.74 · Cited by 24
Zeng, L., Liao, Q., Zhao, H., Jiang, S., Yang, X., Tang, H., He, Q., Yang, X., Fang, S., He, J., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0566 · Cited by 24
Prion-like proteins and their computational identification in proteomes
Batlle, C., Iglesias, V., Navarro, S., & Ventura, S. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1304214 · Cited by 23
Inhibition of amyloid formation of the Nucleoprotein of SARS-CoV-2Preprint
Tayeb-Fligelman, E., Cheng, X., Tai, C. E., Bowler, J. T., Griner, S. L., Sawaya, M. R., Seidler, P. M., Jiang, Y. X., Lu, J., Rosenberg, G. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.05.434000 · Cited by 25
Self-citationNavalkar, A., Paul, A., Sakunthala, A., Pandey, S., Dey, A. K., Saha, S., Sahoo, S., Jolly, M. K., Maiti, T. K., & Maji, S. K. (2022) · Journal of Cell Science · doi:10.1242/jcs.259500 · Cited by 23
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911023 · Cited by 23
Morfino, P., Aimo, A., Vergaro, G., Sanguinetti, C., Castiglione, V., Franzini, M., Perrone, M. A., & Emdin, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041129 · Cited by 23
Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
Teveroni, E., Lucà, R., Pellegrino, M., Ciolli, G., Pontecorvi, A., & Moretti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1233179 · Cited by 23
Targeting mutant p53 for cancer therapy
Oren, M., Tal, P., & Rotter, V. (2016) · Aging · doi:10.18632/aging.100992 · Cited by 23
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 29
Experimental models for ovarian cancer research
Tsang, S. I., Hassan, A. A., To, S. K. Y., & Wong, A. S. T. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113150 · Cited by 22
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
Huang, Y., Wang, L., Zhou, Y., Bai, J., Li, N., Su, Z., & Cheng, X. (2025) · Cells · doi:10.3390/cells14080583 · Cited by 25
Biomolecular Condensation: A New Phase in Cancer Research
Chakravarty, A. K., McGrail, D. J., Lozanoski, T. M., Dunn, B. S., Shih, D. J. H., Cirillo, K. M., Cetinkaya, S. H., Zheng, W. J., Mills, G. B., Yi, S. S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1605 · Cited by 22
Sengupta, S., Ghufran, S. M., Khan, A. A., Biswas, S., & Roychoudhury, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02831-4 · Cited by 20
Organizing biochemistry in space and time using prion-like self-assembly
Jakobson, C. M., & Jarosz, D. F. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.11.012 · Cited by 18
Sengupta, S., Singh, N., Paul, A., Datta, D., Chatterjee, D., Mukherjee, S., Gadhe, L. G., Devi, J., Yeshwant, M., Jolly, M. K., et al. (2023) · Journal of Cell Science · doi:10.1242/jcs.261017 · Cited by 20
Karthikeyan, S., Lantvit, D. D., Chae, D. H., & Burdette, J. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11499 · Cited by 20
Mouse modelling of the MDM2/MDMX−p53 signalling axis
Tackmann, N. R., & Zhang, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx006 · Cited by 21
Role of Thiol Reactivity for Targeting Mutant p53
Zhang, Q., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.06.013 · Cited by 20
Lu, P., Bowman, K. E. R., Brown, S. M., Joklik-Mcleod, M., Mause, E. R. V., Nguyen, H. T. N., & Lim, C. S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00136 · Cited by 20
Psilopatis, I., Sykaras, A. G., Mandrakis, G., Vrettou, K., & Theocharis, S. E. (2022) · Biomedicines · doi:10.3390/biomedicines11010001 · Cited by 20
Cai, X., Li, Y., Zheng, J., Liu, L., Jiao, Z., Lin, J., Jiang, S., Lin, X., & Sun, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1291559 · Cited by 19
Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22
Biophysical characterization of p53 core domain aggregates
Lima, I., Navalkar, A., Maji, S. K., Silva, J. L., de Oliveira, G. A. P., & Cino, E. A. (2019) · Biochemical Journal · doi:10.1042/bcj20190778 · Cited by 19
Cell-mediated immune resistance in cancer
Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 20
Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy
Hibino, E., & Hiroaki, H. (2022) · Biophysical Reviews · doi:10.1007/s12551-021-00915-5 · Cited by 17
Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
Marques, M. A., de Andrade, G. C., Silva, J. L., & de Oliveira, G. A. P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.944955 · Cited by 16
Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics
Maity, D. (2022) · ChemMedChem · doi:10.1002/cmdc.202200499 · Cited by 18
A unique chaperoning mechanism in class A JDPs recognizes and stabilizes mutant p53
Zoltsman, G., Dang, T. L., Kuchersky, M., Faust, O., Silva, M. S., Ilani, T., Wentink, A. S., Bukau, B., & Rosenzweig, R. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.018 · Cited by 18
Research progress and application of liver organoids for disease modeling and regenerative therapy
Hu, Y., Geng, Q., Wang, L., Wang, Y., Huang, C., Fan, Z., & Kong, D. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02455-3 · Cited by 21
da Paz, M. M., Ferretti, G. D. S., Martins-Dinis, M. M. D. C., Ferreira, B. I. S., Faier-Pereira, A., Barnoud, T., Moreira, O. C., Silva, J. L., Cordeiro, Y., & Rangel, L. P. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1165132 · Cited by 17
Kozaki, I., Shimizu, K., & Honda, H. (2017) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2017.03.013 · Cited by 16
A History and Current Understanding of Acute Erythroid Leukemia
Alexander, C. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.04.011 · Cited by 15
Metadata
- Authors
- Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., Pellegrini, M., Memarzadeh, S., & Eisenberg, D. S.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of California, Los Angeles (US)
- Corresponding author
- Memarzadeh, Sanaz
- Eisenberg, David S.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 29
- Issue
- 1
- Pages
- 90-103
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4733364
- OpenAlex
- W2207474307
- Cited by
- 341
- References
- 61
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 29 · 2023: 31 · 2022: 42 · 2021: 29 · 2020: 32 · 2019: 35 · 2018: 39 · 2017: 33 · 2016: 28
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH (1S10RR023718-01A2, AG-029430, R01CA183877)
- Pardee Foundation
- National Center for Advancing Translational Science (UL1TR000124)
- American Cancer Society (RSG-14-217-01-TBG)
- National Science Foundation (MCB 0958111)
- Jonsson Cancer Center Foundation
- Lynne Cohen Foundation
- Phase One Foundation
- Ovarian Cancer Circle Inspired by Robin Babbini
- Leath L. and Marcia L. Millen Family Fund
- G.O. Discovery Lab Foundation
- HHMI
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, amyloid-like aggregation, p53 missense mutations, cell-penetrating peptides, high-grade serous ovarian cancer, organoids, xenografts, cell proliferation, apoptosis
- MeSH terms
- Animals, Cell Line, Cells, Cultured, Disease Models, Animal, Female, Humans, Mice, Transgenic, Ovarian Neoplasms, Tumor Suppressor Protein p53, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
